| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 952 | 639 | 259 |
| Full Text Views | 13 | 1 | 0 |
| PDF Downloads | 12 | 2 | 0 |
Phase I Safety and Immunogenicity Testing of Clinical Lots of the Synthetic Plasmodium falciparum Vaccine SPF66 Produced under Good Manufacturing Procedure Conditions in the United States
Daniel M. Gordon
Daniel M. Gordon
Department of Immunology, Walter Reed Army Institute of Research, Washington, District of Columbia
Search for other papers by Daniel M. Gordon in
Current site
Google Scholar
PubMed
Search for other papers by Daniel M. Gordon in
Current site
Google Scholar
PubMed
Patrick E. Duffy
Patrick E. Duffy
Department of Immunology, Walter Reed Army Institute of Research, Washington, District of Columbia
Search for other papers by Patrick E. Duffy in
Current site
Google Scholar
PubMed
Search for other papers by Patrick E. Duffy in
Current site
Google Scholar
PubMed
D. Gray Heppner
D. Gray Heppner
Department of Immunology, Walter Reed Army Institute of Research, Washington, District of Columbia
Search for other papers by D. Gray Heppner in
Current site
Google Scholar
PubMed
Search for other papers by D. Gray Heppner in
Current site
Google Scholar
PubMed
Jeffrey A. Lyon
Jeffrey A. Lyon
Department of Immunology, Walter Reed Army Institute of Research, Washington, District of Columbia
Search for other papers by Jeffrey A. Lyon in
Current site
Google Scholar
PubMed
Search for other papers by Jeffrey A. Lyon in
Current site
Google Scholar
PubMed
Joseph S. Williams
Joseph S. Williams
Department of Immunology, Walter Reed Army Institute of Research, Washington, District of Columbia
Search for other papers by Joseph S. Williams in
Current site
Google Scholar
PubMed
Search for other papers by Joseph S. Williams in
Current site
Google Scholar
PubMed
Dale Scheumann
Dale Scheumann
Department of Immunology, Walter Reed Army Institute of Research, Washington, District of Columbia
Search for other papers by Dale Scheumann in
Current site
Google Scholar
PubMed
Search for other papers by Dale Scheumann in
Current site
Google Scholar
PubMed
Linda Farley
Linda Farley
Department of Immunology, Walter Reed Army Institute of Research, Washington, District of Columbia
Search for other papers by Linda Farley in
Current site
Google Scholar
PubMed
Search for other papers by Linda Farley in
Current site
Google Scholar
PubMed
Daniel Stacey
Daniel Stacey
Department of Immunology, Walter Reed Army Institute of Research, Washington, District of Columbia
Search for other papers by Daniel Stacey in
Current site
Google Scholar
PubMed
Search for other papers by Daniel Stacey in
Current site
Google Scholar
PubMed
J. David Haynes
J. David Haynes
Department of Immunology, Walter Reed Army Institute of Research, Washington, District of Columbia
Search for other papers by J. David Haynes in
Current site
Google Scholar
PubMed
Search for other papers by J. David Haynes in
Current site
Google Scholar
PubMed
Jerald C. Sadoff
Jerald C. Sadoff
Department of Immunology, Walter Reed Army Institute of Research, Washington, District of Columbia
Search for other papers by Jerald C. Sadoff in
Current site
Google Scholar
PubMed
Search for other papers by Jerald C. Sadoff in
Current site
Google Scholar
PubMed
W. Ripley Ballou
W. Ripley Ballou
Department of Immunology, Walter Reed Army Institute of Research, Washington, District of Columbia
Search for other papers by W. Ripley Ballou in
Current site
Google Scholar
PubMed
Search for other papers by W. Ripley Ballou in
Current site
Google Scholar
PubMed
Two clinical lots of alum-adsorbed SPf66 vaccine produced in the United States were evaluated in separate, open-label, Phase I clinical trials involving 15 healthy, malaria-naive, 18–45-year old men and women. Subjects received 2 mg doses subcutaneously in alternate arms at 0, one, and six months. Safety was assessed by monitoring local and systemic reactions and laboratory parameters. The most common side effects were erythema and local tenderness at the site of injection, which increased in frequency with subsequent doses of vaccine. These local reactions were considered mild and resolved within 24–48 hr. Eleven of 14 volunteers who received all three doses of vaccine seroconverted by enzyme-linked immunosorbent assay. The distribution of high, medium, and low nonresponders was comparable with that seen in trials of Colombian-produced vaccine. One high responder developed antibodies reactive with asexual stage parasite antigens by immunofluorescence and immunoblot. The results indicated that at full adult doses, SPf66 of U.S. origin is mildly reactogenic and induces immune responses similar to those reported for SPf66 of Colombian origin.
Author Notes
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 952 | 639 | 259 |
| Full Text Views | 13 | 1 | 0 |
| PDF Downloads | 12 | 2 | 0 |